Investor Presentation

July 28, 2026 The Manager BSE Limited Listing Department Corporate Relationship Department National Stock Exchange of India Limited Floor 25, P.J. Towers Exchange Plaza, 5th Floor Dalal Street Plot No. C1, ‘G’ Block, Bandra-Kurla Complex Mumbai 400 001. Bandra (East), Mumbai 400 051. Symbol: RPGLIFE Scrip code: 532983 Dear Sir/Madam, Sub: Investor Presentation - Financial Results Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2026. Kindly take the above on record. Thanking you, Yours faithfully, For RPG Life Sciences Limited Rajesh Shirambekar Head – Legal & Company Secretary Encl: as above Q1 FY27 Performance RPG Life Sciences Investors’ Presentation July 2026 Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward- looking statements. The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice. This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations. RPG Group: Powered by Passion, Driven by Ethics RPG Enterprises was founded in 1979. The group currently operates various businesses in Infrastructure, Technology, Life Sciences, Plantations and Tyre industries. The group has business history dating back to 1820 AD in banking, textiles, jute and tea. The Group grew in size and strength with several acquisitions in the 1980s and 1990s. RPG Group is one of India’s fastest growing conglomerates with 31,000+ employees, presence in 135+ countries and annual gross revenues of USD 5.2 Bn EPC major in One of India’s Global Integrated Technology One of India’s infrastructure leading tyre technology pharma solutions largest segments like manufacturers consulting and company in company plantation T&D, Civil, IT services formulations catering to companies Transportation, company and synthetic energy and producing tea, Oil & Gas, APIs infrastructure rubber, etc. Renewables & Cables RPG Life Sciences: An Integrated Pharmaceutical Company RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. Leader in Domestic Formulations (DF) Immunosuppressants Develop, manufacture and market APIs branded formulations in India & 14% Nepal Therapies represented by High Equity Brands International Domestic Formulations Domestic International Formulations (IF) Dom(IeFs)tic Formulations Formulation 18% (DF) Develop, manufacture and market Formulation s (DF) 65% 68% oral solid dosage formulations in the 50+ Markets Presence 66% generics and branded generics space Manufacturing Facilities – APIs API and Formulations Develop, manufacture and sell high value synthetic APIs in the general therapeutic category 1445+ Employees RPG Life Sciences: Strong Product Portfolio, Textbook brands; focus on chronic & specialty therapies Key Therapies DF Key Products Legacy Portfolio New Portfolio Nephrology Life Cycle Immunosuppressants Textbook Brands Specialty Chronic Management (Existing Products) Rheumatology Trastuzumab Azathioprine Sacubitril+ Valsartan Azathioprine Oncology Adalimumab Spironolactone Vildagliptin Pain Management Bevacizumab Mycophenolate Mofetil Diphenoxylate HCl Teneligliptin Gastroenterology Rituximab Dapagliflozin Naproxen Neuropsychiatry Cyclosporine Tofacitinib Haloperidol Cardio- Diabeto Solifenacin Ferric Carboxymaltose Urology Tacrolimus Disopyramide Phosphate Denosumab IF Key Products Generics - Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline and so on Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune ME, Dyzantil, Dipsope and so on APIs Key Products Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole and so on Business Operations Quality – Centric Operations with Scalable Capabilities Formulation - Ankleshwar, Gujarat API - Navi Mumbai, Maharashtra • Located in the industrial town of Ankleshwar in Gujarat, India; • The API Manufacturing facility consists of three district units, each the Multipurpose plant with dedicated product lines for Oral aligned to specific market requirements. MF2 operates as a Dosage forms including tablets, liquids, and powder. This dedicated immunosuppressant unit, while MF3 and MF4 are [Showing first 8,000 characters — download PDF for full document]